Linapride E 10mg/5mg Tablet
By Linapride E
Rx
10 Tablet in a Strip

Composition
Empagliflozin(10mg) + Linagliptin(5mg)

Manufacturer - Micro Labs Ltd
27, RACE COURSE ROAD, BANGALORE-560 001, INDIA

Expires on or after
September, 2027

liver
Linapride E 10mg/5mg Tablet is generally considered safe for use in patients with liver disease. It is advised that there is no need for dose adjustment when using this medication. However, it is important to note that the use of Linapride E 10mg/5mg Tablet is not recommended for individuals with severe hepatic impairment, as there have not been sufficient studies conducted in such cases. Always consult with your healthcare provider before using Linapride E 10mg/5mg Tablet, especially if you have severe liver issues.

kidney
Linapride E 10mg/5mg Tablet requires caution in patients with kidney disease. Dose adjustment may be necessary. Consult your doctor before use. Avoid in severe kidney disease or dialysis.

alcohol
It is advised to avoid consuming alcohol while taking Linapride E 10mg/5mg Tablet due to potential risks.

driving
It is not clear if Linapride E 10mg/5mg Tablet affects driving abilities. Avoid driving if you have symptoms impacting concentration and reaction time while using this medication.

pregnancy
Linapride E 10mg/5mg Tablet may not be safe to use during pregnancy. Animal studies have shown potential harm to the developing baby. Your doctor will assess the benefits and risks before prescribing. Please consult your doctor regarding its use during pregnancy.

breastfeeding
Linapride E 10mg/5mg Tablet may be unsafe while breastfeeding, as it could pass into breastmilk and harm the baby. It is advisable to consult a healthcare provider before using this medication during breastfeeding.
| Habit Forming | No |
| Chemical Class | - |
| Therapeutic Class | ANTI DIABETIC |
| Action Class | - |
₹121.92
₹143.44
15% OFF
Inclusive of all taxes
Content verified by

Dr. Preeti Kumar
MBBS, DGO - Obstetrics and Gynaecology, DNB - Obstetrics and Gynaecology
Last update on 01-Oct-2024
